Wed, Sep 17, 2014, 12:01 AM EDT - U.S. Markets open in 9 hrs 29 mins

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • ghdx150coming ghdx150coming Jan 7, 2014 12:07 PM Flag

    Australian Partner just announced

    Announcing the distribution agreement with Genomic Health, STA Chief Executive Officer Carlo Montagner said the Oncotype DX assay was a high calibre tool for women diagnosed with early stage breast cancer who sought to avoid chemotherapy where possible, because it provided information about the likelihood of a cancer recurrence.

    "This ground breaking test, which has been universally adopted in the U.S., helps women make informed decisions," he said.

    "Many Australian women with early stage breast cancer have endured debilitating chemotherapy regimens as a precautionary measure. This test will arm women and their physicians with more information about the likelihood of the patient benefitting from chemotherapy, as well as recurrence, helping them make a well-informed treatment decision."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The National Comprehensive Cancer Network (NCCN)3, the American Society of Clinical Oncology (ASCO)4, St Gallen5 , and the European Society for Medical Oncology (ESMO)6 have all incorporated the Oncotype DX test into their guidelines. In the U.K., the National Institute for Health and Care Excellence (NICE) has recommended Oncotype DX as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients with early-stage, hormone-receptor-positive, invasive breast cancer.7

      "The Oncotype DX technology has played a critical role in predicting benefit of chemotherapy for more than 400,000 oestrogen-receptor-positive breast cancer patients globally in the past 10 years," said Peter Zuendorf, Vice President, International, Genomic Health. "As adoption of Oncotype DX continues to grow, we are delighted to enter this partnership to broaden patient access to this unique test and the important information it provides to enable more individualised breast cancer treatment."

      This commercial arrangement between STA and Genomic Health commences from 1st January 2014.

      Sentiment: Strong Buy

 
GHDX
28.94+0.66(+2.33%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.